Latest News for: q32

Edit

Q32 Bio: Q3 Earnings Snapshot

The Call 07 Nov 2024
WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Q32 Bio Inc ... The results did not meet Wall Street expectations ... .
Edit

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update Form 8 K (Q32 Bio Inc)

Public Technologies 07 Nov 2024
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update ... WALTHAM, Mass.-November 7, 2024 - Q32 Bio Inc ... About Q32 Bio ... Availability of Other Information About Q32 Bio ... Q32 BIO INC ... Q32 BIO INC ... Q32 Bio Inc.
Edit

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

PR Newswire 07 Nov 2024
7, 2024 /PRNewswire/ -- Q32 Bio Inc ... About Q32 Bio ... Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives ... Q32 BIO INC ... Q32 BIO INC.
Edit

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q) (Q32 Bio Inc)

Public Technologies 07 Nov 2024
... business and operations of Q32 Bio Inc ... Homology changed its name to Q32 Bio Inc., or Q32, and Legacy Q32, which remains as a wholly-owned subsidiary of Q32, changed its name to Q32 Bio Operations Inc.
Edit

Supplemental Prospectus - Form 424B3 (Q32 Bio Inc)

Public Technologies 07 Nov 2024
... business and operations of Q32 Bio Inc ... Homology changed its name to Q32 Bio Inc., or Q32, and Legacy Q32, which remains as a wholly-owned subsidiary of Q32, changed its name to Q32 Bio Operations Inc.
Edit

Statement of Changes in Beneficial Ownership - Form 4 (Q32 Bio Inc)

Public Technologies 17 Oct 2024
) Ownership Submission FORM 4. Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... 1 ... 2 ... Q32 Bio Inc ... Q32 BIO INC ... 3 ... 4 ... Q32 BIO INC ... Q32 Bio Inc.
Edit

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at ...

Victoria Advocate 14 Oct 2024
-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 -- ....
Edit

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

PR Newswire 14 Oct 2024
14, 2024 /PRNewswire/ -- Q32 Bio Inc ... ADX-097, the lead product candidate from Q32 Bio's tissue-targeted complement inhibitor platform, is a humanized anti-C3d mAb fusion protein ... About Q32 Bio ... Availability of Other Information About Q32 Bio.
Edit

Q32 Bio: Q2 Earnings Snapshot

The Call 08 Aug 2024
WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Q32 Bio Inc ... The results did not meet Wall Street expectations ... .
Edit

Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Victoria Advocate 08 Aug 2024
-- Completed enrollment in bempikibart atopic dermatitis (AD) Phase 2 clinical trial and increased trial size to 121 patients based on Part B patient demand -- ....
Edit

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Pharmiweb 11 Jul 2024
WALTHAM, Mass., July 9, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ. QTTB) ("Q32 ... Q32 Bio is currently evaluating bempikibart in two ongoing Phase 2 clinical trials ... About Q32 Bio.
Edit

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart ...

Citizen Tribune 09 Jul 2024
WALTHAM, Mass., July 9, 2024 /PRNewswire/ -- Q32 Bio Inc ... Q32 Bio is currently evaluating bempikibart in two ongoing Phase 2 clinical trials ... About Q32 Bio ... Availability of Other Information About Q32 Bio ... SOURCE Q32 Bio.

Most Viewed

×